Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
[2] Dr Alessandro Riva, MD, joined Transgene in 2022 as Chairman of the Board of Directors.
Transgene owns two technological platforms: The Company has several clinical-stage products in its portfolio.
2- TG4001 : is a therapeutic vaccine designed to express the E6 and E7 antigens of the HPV-16 virus (human papillomavirus type 16).
[12] Transgene is currently evaluating the full study results in detail to determine the best way forward for this program[13].